News | July 31, 2025
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
For patients with resectable early-stage gastric and gastroesophageal junction cancers
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Subscribe To Our Newsletter & Stay Updated
